GSK3B and prostate cancer: Notably, the immunohistochemical analysis of 499 prostate cancer cases revealed that elevated cytoplasmic (but not nuclear) GSK3β expression correlates with aggressive disease features, such as advanced stage, lymph node metastasis, extracapsular extension, higher Gleason scores, and reduced recurrence-free survival over 12 years [30].